

HHS Public Access

Author manuscript *Mult Scler*. Author manuscript; available in PMC 2022 August 01.

Published in final edited form as:

Mult Scler. 2022 August ; 28(9): 1330–1339. doi:10.1177/13524585211069926.

Gene-environment interactions increase the risk of pediatriconset multiple sclerosis associated with ozone pollution

Amin Ziaei¹, Amy M. Lavery², Xiaorong MA Shao³, Cameron Adams³, T. Charles Casper⁴, John Rose⁴, Meghan Candee⁴, Bianca Weinstock-Guttman⁵, Greg Aaen⁶, Yolanda Harris⁷, Jennifer Graves⁸, Leslie Benson⁹, Mark Gorman⁹, Mary Rensel¹⁰, Soe Mar¹¹, Tim Lotze¹², Benjamin Greenberg¹³, Tanuja Chitnis¹⁴, Janace Hart¹, Amy T. Waldman², Lisa F. Barcellos³, Emmanuelle Waubant¹ US Network of Pediatric MS Centers

¹University of California San Francisco, San Francisco, California

²Division of Child Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

³Genetic Epidemiology and Genomics Laboratory and Divisions of Epidemiology and Biostatistics, School of Public Health, University of California, Berkeley, Berkeley, California

⁴University of Utah, Salt Lake City, Utah

⁵Buffalo General Hospital, State University of New York at Buffalo, Buffalo, New York

⁶Loma Linda University Children's Hospital, Loma Linda, California

⁷University of Alabama, Tuscaloosa, Alabama

⁸University of California San Diego, San Diego, California

⁹Pediatric MS and Related Disorders Program, Boston Children's Hospital, Boston, Massachusetts

¹⁰Cleveland Clinic, Cleveland, Ohio

¹¹Washington University in St. Louis, St. Louis, Missouri

¹²Texas Children's Hospital, Houston, Texas

¹³University of Texas Southwestern Medical Center, Dallas, Texas

¹⁴Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

Abstract

Background: We previously reported a relationship between air pollutants and increased risk of pediatric-onset MS (POMS). Ozone is an air pollutant that may play a role in MS pathoetiology. *CD86* is the only non-HLA gene associated with POMS for which expression on antigen-presenting cells (APC) is changed in response to ozone exposure.

Objective: To examine the association between county-level ozone and POMS, and the interactions between ozone pollution, *CD86* and *HLA-DRB1*15*, the strongest genetic variant associated with POMS.

Methods: Cases and controls were enrolled in the Environmental and Genetic Risk Factors for Pediatric MS study of the US Network of Pediatric MS Centers. County-level modeled ozone data were acquired from the CDC's Environmental Tracking Network. Participants were assigned ozone values based on county of residence. Values were categorized into tertiles based on healthy controls. The association between ozone tertiles and having MS were assessed by logistic regression. Interactions between tertiles of ozone level and the GG genotype of the rs928264 (G/A) single nucleotide polymorphism (SNP) within *CD86*, and the presence of *DRB1*15:01 (DRB1*15)* on odds of POMS was evaluated. Models were adjusted for age, sex, genetic ancestry, and mother's education. Additive interaction was estimated using relative risk due to interaction (RERI) and attributable proportions (AP) of disease were calculated.

Results: 334 POMS cases and 565 controls contributed to the analyses. County-level ozone was associated with increased odds of POMS (odds ratio (OR) 2.47, 95%CI 1.69–3.59 and 1.95, 95%CI 1.32–2.88 for the upper two tertiles, respectively, compared with the lowest tertile). There was a significant additive interaction between high ozone tertiles and presence of *DRB1*15*, with a RERI of 2.21 (95%CI 0.83–3.59) and an AP of 0.56 (95%CI 0.33–0.79). Additive interaction between high ozone tertiles and the *CD86* GG genotype was present, with a RERI of 1.60 (95%CI 0.14–3.06) and an AP of 0.37 (95%CI 0.001–0.75) compared to the lowest ozone tertile. AP results indicated that approximately half of the POMS risk in subjects can be attributed to the possible interaction between higher county-level ozone carrying either *DRB1*15* or the *CD86* GG genotype.

Conclusions: In addition to the association between high county-level ozone and POMS, we report evidence for additive interactions between higher county-level ozone and *DRB1*15* and the *CD86* GG genotype. Identifying gene-environment interactions may provide mechanistic insight of biological processes at play in MS susceptibility. Our work suggests a possible role of APCs for county-level ozone induced POMS risk.

Keywords

Pediatric onset; multiple sclerosis; ozone pollution; gene-environment interaction; *CD86*; *DRB1*15*

Introduction:

Accumulating evidence points to both genetic and environmental factors contributing to multiple sclerosis (MS) onset (1). The missing heritability reported for MS may partly be explained by gene-environment (GxE) interactions.

The study of GxE interactions in children offers important advantages over adult studies in terms of temporality, i.e. exposure time closer to disease onset, and less irrelevant exposures due to younger age (1,2). We have previously reported a strong association between air pollution and pediatric-onset MS (POMS) (2,3). Ozone which contributes to air pollution is a major global health hazard (4) and may play an important role in MS

pathoetiology through several biological processes (5–8). A single study has reported an association between ozone and adult MS susceptibility (9). Also, In the recent Canadian Census Health and Environment Cohort (CanCHEC) analysis, higher death attributable to ozone exposure is reported in MS compared to other neurological diseases (10). Although individual genetic make-up may increase the biological impact of environmental exposures, the genetic variants increasing the association of air pollutants with MS risk have not been studied. Our Network has previously reported that *HLA-DRB1*15:01 (DRB1*15)* is strongly associated with POMS risk and that absence of *HLA-A*02* has a modest effect. In addition, 28 non-HLA variants reported for adult MS are also associated with POMS risk (11). Among genes with variants associated with POMS, *CD86* is the only one for which expression changes in response to ozone exposure (12).

In this study, we sought to assess the association between county-level ozone (hereafter referred to as ozone) and POMS risk and determine possible genetic interactions with ozone levels, focusing on the two top HLA risk factors (DRB1*15 and A*02) and CD86 which expression is modified by ozone exposure. Identifying GxE interactions might provide insight into biological mechanisms that are involved in MS pathoetiology.

Method:

Study Population:

Pediatric MS cases who had disease onset before the age of 18 years were enrolled in this multi-center case-control study of pediatric MS risk factors between 2011 and 2017 (3). All the cases were ascertained by at least two pediatric MS experts from the US pediatric MS network. All samples were tested for MOG-IgG and AQP4 antibodies at Mayo Clinic, and positive cases were excluded. Frequency matched healthy controls younger than 20 years were recruited from the general and subspecialty pediatric clinics at participating institutions during the same period of time as the cases. Inclusion criteria for controls included the absence of autoimmune disease and no first-degree relatives with MS. Participants and their families completed a detailed environmental questionnaire (http://www.usnpmsc.org/ Documents/EnvironmentalAssessment.pdf) including places of residence since birth and provided blood samples for genetic analysis (9). The institutional review boards at the participating sites have approved the study. Consent and assent (when appropriate) were obtained for each subject and their parent.

Environmental Data:

The CDC's Environmental Health Tracking Network provides modelled US county-level values of ozone (13). Each measure contains a population-weighted mean value for the county. In this study, we used the population-weighted mean values for each county in 2014, the mid-point for our study enrollment. SAS statistical software (version: 9.3) was used to assign ozone level values to each participant based on their county of residence. Population-weighted indexes for air pollutants provide a refined representation of the exposure of the study population since they give proportionately greater weight to the air pollution experienced where most people live (14,15). Ozone levels were categorized into tertiles based on healthy control values with the lowest tertile serving as the reference category.

Genetic data:

Each study participant has been genotyped by Infinium 660K BeadChip or HumanOmniExpress BeadChip. Stringent quality control (QC) measures and comparison of sample genotypes across two Illumina platforms were performed using PLINK v.1.9. The alignment, phasing, imputation, and variant filtering were done as described previously (11). The *HLA-A*02* (rs2975033) tagging SNP was imputed. The allele 'A' of rs2975033 has been reported to be in perfect linkage disequilibrium (r^2 =0.97) with the *HLA-A*02* allele (14). Therefore, the GG genotype of rs2975033 has been considered as absence of *HLA-A*02* in subjects. The participants were categorized based on no carriage of any *HLA-A*02* allele vs any carriage. In addition, the subjects were classified according to presence of two risk alleles 'G' of *CD86* SNP (rs928264 G/A) which is associated with POMS risk (11). Furthermore, carrying the GG genotype of rs928264 has been reported to increase the expression of *CD86* (15). Therefore, *CD86* SNP genotyping was dichotomized according to the presence of GG genotype vs. other (GA and AA genotypes).

In addition, DNA samples of all subjects have also been genotyped for *DRB1* status, as previously published (16). *DRB1* status was dichotomized according to the presence of one or more *HLA-DRB1*15* alleles vs no carriage.

SNP weighting method (17) has been used to estimate the percentage of genetic ancestry related to four major populations (European, East Asian, West African, and Native American).

Statistical Analysis:

The odds of having POMS associated with ozone level tertiles, presence of *HLA-DRB1*15*, absence of *HLA-A *02* and GG genotype of *CD86* SNP were assessed separately using logistic regression models adjusted for age, sex, genetic ancestry, and mother's education as a proxy of socioeconomic status (SES). We tested for additive interaction between high ozone levels (tertiles 2 and 3) and genotype status in several logistic regression models calculating the relative excess risk due to interaction (RERI) and the attributable proportion (AP) of disease due to interaction. Confidence intervals for all estimates were calculated using published methods (18,19). A multiplicative interaction term was also created and added to logistic regression models to assess for the presence of multiplicative interaction. All statistical analyses were performed using Stata 15.0 (Stata Corp, College Station, TX). To calculate RERI and AP and their confidence intervals, we used adjusted odds ratio from our logistic regression models. We first ran our adjusted logistic regression models in Stata and then used the "nlcom" command according to the formula of RERI and AP as described in (19). The output included the adjusted estimates of RERI and AP, their 95% confidence interval, and P-value.

Results:

Participant's characteristics

A total of 334 POMS cases and 565 healthy controls with valid US zip codes contributed to this analysis. Table 1 depicts the characteristics of the study participants. Healthy controls

were overall frequency matched to POMS cases for age, sex, and race but more were Hispanics and more had mother's education less than high school in the POMS group (Table 1). POMS cases were significantly more likely to live in a county with assigned "tertiles 2 and 3" ozone level (82% of POMS cases vs. 66% in healthy controls). There were 16 POMS cases and ten controls drop-out in our logistic regression model because of missing genetic ancestry data estimations.

Genetic characteristics

Compared to healthy children, children with MS were more likely to have at least one *HLA-DRB1*15* allele (Table 2). In addition, higher proportion of POMS participants had the GG genotype of *CD86* POMS-risk SNP (rs9282641) compare to healthy controls (Table 2). Based on the available imputed genotype for *HLA-A*02*, the proportion of participants without any *HLA-A*02* alleles was higher in POMS (61%) than healthy subjects (56%).

High ozone levels associated with higher odds of POMS

Figure 1 displays odds ratios (ORs) based on logistic regression models adjusted for age, sex, genetic ancestry and mother's education. High ozone levels (tertiles 2 and 3) more than doubled the odds of having MS (adjusted OR 2.47, 95%CI: 1.69–3.59 and 1.95, 95%CI: 1.32–2.88, respectively). In addition, the presence of *HLA-DRB1*15* and the *CD86* SNP GG genotype were also associated with POMS risk (adjusted OR of 2.28, 95%CI: 1.75–2.96 and 1.96, 95%CI: 1.32–2.93, respectively). The absence of *HLA-A*02* alleles tended to increase odds of POMS (adjusted OR of 1.22, 95%CI: 0.93–1.59).

Furthermore, using a continuous ozone variable in our adjusted logistic regression model, each unit increase in population-weighted ozone levels increase POMS risk by 2%.

Supplementary Figure 1 illustrates predicted probabilities in an adjusted logistic regression model based on the marginal standardization method implemented by the 'margins' command in Stata. Standard errors have been calculated by delta methods (20). The risk of having POMS increased in two upper tertiles (high ozone exposure) in comparison to low ozone exposure (tertile 1). Supplementary Figure 2 indicates comparable odds ratios of developing POMS with different models adjusted for genetic background.

Assessment of gene-environment interactions

In Table 3, we stratified analyses of high ozone levels (tertiles 2 and 3) in comparison to the other genetic risk factors (presence of *HLA-DRB1*15*, the GG genotype of *CD86* SNP, and absence of *HLA-A*02*) in POMS cases compared to healthy controls. Without high ozone exposure, the presence of *HLA-DRB1*15* alleles did not significantly increase the odds of POMS. When both *HLA-DRB1*15* alleles and high ozone exposure were present, the odds of having POMS increased to 3.89 (95% CI: 2.47–6.12). The RERI for high ozone category and presence of *HLA-DRB1* alleles (2.21, 95% CI: 0.83–3.59) suggested an additive interaction and indicates that the risk fraction in presence of both ozone and *HLA-DRB1*15* exceeds the addition of risks. The attributable proportion (AP) indicated that approximately 50% (AP 0.56, 95% CI: 0.33–0.79) of the POMS risk in those with *DRB1* haplotype and high ozone levels was attributable to the interaction between these risk

factors. Without high ozone exposure, the presence of the GG genotype of *CD86* SNP did not significantly increase the odds of having POMS. Conversely, without the GG genotype of *CD86* SNP, high ozone exposure was not associated with increased odds of POMS. When both GG genotype of *CD86* SNP and high ozone exposure were present, the odds ratio of POMS increased to 4.06 (95% CI: 1.36–12.14), indicating an additive interaction with a RERI of 1.60 (95% CI: 0.14–3.06). We also detected a statistically significant interaction between high ozone levels and absence of *HLA-A* *02 with regard to POMS risk (RERI 1.55, 95% CI: 0.78–2.32, AP 0.52, 95% CI: 0.15–0.89).

Table 4 shows multiplicative interactions for high ozone levels with genetic risk factors in various logistic regression models adjusted for age, sex, genetic ancestry, and mother's education. Although there was evidence for multiplicative interactions between high county-ozone values and presence of *HLA-DRB1* and also absence of *HLA-A*02* (p=0.03 and 0.02, respectively), the interaction term in the logistic regression model adjusted for the presence of the *CD86* SNP GG genotype was not statistically significant suggesting that the interaction present between high ozone levels and this genetic risk factor (CD86 SNP GG genotype) is not multiplicative. According to Log-likelihood and Pseudo R2 values, the best logistic regression model to predict POMS risk is model 2 (with the interaction term, Ozone X DRB1*15 +). In addition, higher Log-likelihood, and Pseudo R2 values indicate that model 3 (with the interaction term, Ozone X CD86 GG +) is a better model than model 1 (without any interaction terms).

Discussion:

In this study, we demonstrated that children who live in areas with high ozone pollution may be at higher risk of having POMS. Furthermore, we identified the potential for geneenvironment interactions with high ozone levels in POMS for three genetic risk factors (presence of *HLA-DRB15*, absence of *HLA-A*02* and the GG genotype of *CD86* SNP).

In a large population-based cohort, the ozone level was the only air pollutant associated with increased adult MS incidence (9). In another multi-pollutant study, ozone levels was associated with increased risk of relapse in adult MS patients (21). In the present study as the first study in children, we showed that high ozone levels increased the risk of POMS (OR of ~2), expanding our previous work that air pollution is strongly associated with POMS susceptibility (2). Ozone pollution might play an important role in MS pathoetiology. Not only can ozone induce inflammation and oxidative insult in the central nervous system (CNS) and modulate the immune response (5), it can also impact myelin ultrastructure in *in vitro studies* (6). Furthermore, we demonstrate evidence for additive and multiplicative interactions between HLA-DRB1*15, the strongest genetic risk factor for POMS(11), and high ozone levels. POMS risk associated with high ozone level in those carrying HLA-DRB1*15 exceeds the addition of the separate risks (RERI~2 and AP~0.6). Multiplicative interactions were also detected for these risk factors that highlight strong biological association. Long-term ozone exposure may lead to inflammation and oxidative stress which in turn prime microglia and damage the blood brain barrier (BBB) (8). This lung-brain axis eventually may contribute to CNS autoimmunity (7,8). This is intriguing as the HLA-DRB15:01-binding pocket has a high affinity for CNS autoantigens (22) and

could conceptually explain the interaction of high ozone levels with the *HLA-DRB1*15:01* haplotype. Several interactions between environmental risk factors and *HLA-DRB1* have been reported in MS (1). The most relevant to our study are those related to various sources of lung irritation that may make individuals susceptible to MS such as cigarette smoking, secondhand smoking (23) and exposure to organic solvents (24).

Among non-HLA genes with variants associated with POMS risk (11), *CD86* is the only one for which expression is reportedly influenced by ozone exposure. Ozone exposure increases *CD86* expression on antigen-presenting cells (APCs) (12). Carrying the GG genotype of *CD86* related POMS-risk SNP (rs928264) is associated with increased expression as well (15). *CD86* is a co-stimulatory ligand expressed on APCs contributing to T cells proliferation, cytokine secretion (25) and severity of experimental autoimmune encephalitis (EAE) (26). Furthermore, in MS patients higher expression of *CD86* has been reported in B cells (27,28), macrophages (29) and astrocytes (30) that can all serve as APCs. Taken together, high ozone exposure increases the expression of *CD86* and could increase susceptibility to POMS, especially in those carrying the GG genotype (RERI~1.6 and AP~0.4). The GxE interaction we reported, highlights the possible critical role of APCs in high ozone exposure-induced POMS risk.

Although *HLA-* A * 02 is the second major allele associated with adult MS (31), its absence has only modest effect on susceptibility to POMS (11). Individuals without *HLA-A*02* tended to have a higher risk of POMS (adjusted OR 1.22, 95%CI: 0.93–1.59). *HLA-A*02* may modulate the immune response contributing the MS onset (32). In addition, the absence of *HLA-A*02* may increase the negative selection of CNS autoreactive T cells (33). This could explain why we observed a slight additive interaction between high ozone levels and absence of *HLA-A*02* (RERI: 1.55 and AP: 0.52). Furthermore, the absence of *HLA-A*02* may interact with other environmental MS risk factors such as Epstein-Barr virus (EBV) infection, cigarette smoking, passive smoking and obesity (1).

The risk of developing POMS among subjects with genetic susceptibility and exposed to high level of ozone is higher than expected risk based on the sum of the risks for each one individually. These additive interactions suggest a potential role for biological synergism of these risk factors (34). From a public health point of view, our results suggest that decreasing ozone exposure in individuals with the genetic risk factors we studied may help decrease MS onset.

The strengths of our study include the large size of our cohort of POMS with frequencymatched controls, the diversity of geographic origin, the careful case ascertainment and the exclusion of confirmed MOG-IgG associated disease (MOGAD) by pediatric MS specialists. The US network of pediatric MS centers are tertiary referral centers; this may result in a selection bias toward more severe or complicated POMS cases. Although those centers serve regional patients from all socioeconomic groups, we adjusted our analyses for mother's education as a proxy of socioeconomic status. In addition, we adjusted our models for genetic ancestry estimations. Other strengths include that we focused the study of GxE interactions on the 2 strongest HLA risk factors for MS and on another genetic variant on the

One of the limitations of our study is the use of population-weighted ozone value as a proxy of long-term ozone exposure rather than a measurement of direct ozone exposure. Individual level factors such as time spent outdoors and travel between counties are less varied than adults but still might impact actual ozone exposure. However, population-weighted indexes are reported to provide acceptable exposure estimation of air pollutants (35). In this study, we used 2014 ozone levels, mid-year of study enrolment, and assigned them to each individual based on county of residence at the time of study enrolment.

Future study with larger sample size would be required to enable three-way interaction analyses. Finally, we were not able to identify another geographically diverse MS cohort to try to replicate our findings as other deeply phenotyped cohorts did not include information on ozone exposure.

In summary, ozone exposure may be an important risk factor for pediatric MS onset, especially among individuals with genetic susceptibility to the disease. Interactions between high ozone levels and the presence of *HLA-DRB1*15*, *CD86* SNP rs928264 GG genotype, and absence of *HLA-A*02* suggest a possible role of APCs and immune-related mechanisms for ozone induced MS risk.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements:

Funding for this work include R01NS071463 (PI Waubant), NMSS HC-1509-06233 (PI Casper), McDonald fellowship award of MSIF (PI Ziaie)

Disclosures:

Dr. Amin Ziaei, Dr. Amy M.Lavery, Ms.Xiaorong Ma Shao, Mr. Cameron Adams, Ms. Janace Hart report no disclosures relevant to the manuscript.

Dr. Gregory Aaen has participated in clinical trials funded by Biogen and Roche.

Dr. Leslie Benson has received funding for research unrelated to this work for a Biogen sponsored clinical trial, and Boston Children's Hospital office of faculty development grant. She has also acted as a paid consultant to the national Vaccine Injury Compensation Program.

Dr. Mark Gorman has participated in clinical trials funded by Roche, Novartis and Biogen and received research funding from Pfizer.

Dr. Manu Goyal receives grant support from the NIH, has IBM stock and has received honoraria and trip reimbursement from Capital Medical University, Beijing, Shandong Madic Technologies Co. Ltd, and the Tancheng Talent Office for brain PET conferences in 2019.

Dr. Jennifer Graves has received grant and clinical trial support from the National MS Society, Race to Erase MS, UCSF CTSI RAP program, Biogen, and Genentech. She has received honoraria from Biogen and Genzyme for non-promotional trainee education events. She has received personal fees from Novartis and Celgene.

Dr. Yolanda Harris reports no disclosures relevant to the manuscript.

Dr. Timothy Lotze has served as a consultant/speaker for Biogen.

Dr. Soe Mar has participated in clinical trials funded by Roche.

Dr. Jayne Ness has participated in clinical trials funded by Novartis, Chugai, and Roche.

Dr. Mary Rensel has served as a consultant and/or received research or patient education funds from Serono, Biogen, Medimmune, Novartis, Genentech, NMSS, Improve Consulting, Kijia and MSAA.

Dr. John Rose has research support from NMSS, NIH, Guthy Jackson Foundation, PCORI, Friends of MS, Biogen, and VA.

Dr. Bianca Weinstock-Guttman has served as a consultant/ speaker for Biogen, Novartis, Genzyme&Sanofi, Genentech, Abbvie, Bayer, EMD Serono; research support from Biogen, Novartis, Genentech, Genzyme &Sanofi, EMD Serono. Mr. Michael Waltz reports no disclosures relevant to the manuscript.

Dr. T. Charles Casper has received research support from Roche.

Dr. Benjamin Greenberg and Dr. Meghan Candee repot no disclosures relevant to the manuscript.

Dr. Tanuja Chitnis is an advisory board member for Biogen, Novartis, and Sanofi-Genzyme; has received research support from the National MS Society, Department of Defense, Guthy Jackson Charitable Foundation, Mallinckrodt, Novartis and Octave; has participated in clinical trials sponsored by Sanofi-Genzyme and Novartis.

Dr. Amy Waldman reports no disclosures relevant to the manuscript. She has participated in multicenter clinical trials and prospective studies funded by Novartis, Ionis, Genentech, and Travere. She has current grant support from the NIH, NMSS, and Pennsylvania Department of Health. She receives royalties from UpToDate.

Dr. Lisa F. Barcellos has current funding for research unrelated to this work from the National MS Society and the National Institutes of Health

Dr. Emmanuelle Waubant has participated in multicenter clinical trials funded by Genentech, Alexion and Biogen. She has current support from the NIH, NMSS, PCORI, CMSC and Race to Erase MS.

References:

- Waubant E, Lucas R, Mowry E, Graves J, Olsson T, Alfredsson L, et al. Environmental and genetic risk factors for MS: an integrated review. Annals of Clinical and Translational Neurology. 2019;6(9):1905–22. [PubMed: 31392849]
- Lavery AM, Waldman AT, Charles Casper T, Roalstad S, Candee M, Rose J, et al. Examining the contributions of environmental quality to pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders [Internet]. 2017 Nov 1 [cited 2020 Apr 22];18:164–9. Available from: http:// www.ncbi.nlm.nih.gov/pubmed/29141802 [PubMed: 29141802]
- Lavery AM, Waubant E, Casper TC, Roalstad S, Candee M, Rose J, et al. Urban air quality and associations with pediatric multiple sclerosis. Annals of Clinical and Translational Neurology. 2018;5(10):1146–53. [PubMed: 30349849]
- Zhang JJ, Wei Y, Fang Z. Ozone pollution: A major health hazard worldwide. Frontiers in Immunology. 2019;10(OCT):1–10. [PubMed: 30723466]
- 5. Jakab GJ, Spannhake Wm. E, Canning BJ, Kleeberger SR, Gilmour MI. The effects of ozone on immune function. Environmental Health Perspectives. 1995;103(SUPPL. 2):77–89.
- Ozbay I, Ital I, Kucur C, Akcilar R, Deger A, Aktas S, et al. Efeitos da terapia com ozônio na regeneração do nervo facial. Brazilian Journal of Otorhinolaryngology. 2017;83(2):168–75. [PubMed: 27174776]
- Esmaeil Mousavi S, Heydarpour P, Reis J, Amiri M, Sahraian MA. Multiple sclerosis and air pollution exposure: Mechanisms toward brain autoimmunity. Medical Hypotheses. 2017;100(2):23– 30. [PubMed: 28236843]
- Mumaw CL, Levesque S, McGraw C, Robertson S, Lucas S, Stafflinger JE, et al. Microglial priming through the lung-brain axis: The role of air pollution-induced circulating factors. FASEB Journal. 2016 May 1;30(5):1880–91. [PubMed: 26864854]

- 9. Bai L, Burnett RT, Kwong JC, Hystad P, van Donkelaar A, Brook JR, et al. Long-term exposure to air pollution and the incidence of multiple sclerosis: A population-based cohort study. Environmental Research. 2018;166(June):437–43. [PubMed: 29940476]
- Zhao N, Pinault L, Toyib O, Vanos J, Tjepkema M, Cakmak S. Long-term ozone exposure and mortality from neurological diseases in Canada. Environment International. 2021 Dec 1;157:106817. [PubMed: 34385046]
- Gianfrancesco MA, Stridh P, Shao X, Rhead B, Graves JS, Chitnis T, et al. Genetic risk factors for pediatric-onset multiple sclerosis. Multiple Sclerosis Journal. 2018 Dec 1;24(14):1825–34. [PubMed: 28980494]
- Hollingsworth JW, Free ME, Li Z, Andrews LN, Nakano H, Cook DN. Ozone activates pulmonary dendritic cells and promotes allergic sensitization through a Toll-like receptor 4-dependent mechanism. Journal of Allergy and Clinical Immunology. 2010;125(5):1167–70. [PubMed: 20394980]
- Daily Census Tract-Level Ozone Concentrations, 2011–2014 | Data | Centers for Disease Control and Prevention [Internet]. [cited 2020 May 30]. Available from: https://data.cdc.gov/Environmental-Health-Toxicology/Daily-Census-Tract-Level-Ozone-Concentrations-2011/372p-dx3h
- Cortes A, Pulit SL, Leo PJ, Pointon JJ, Robinson PC, Weisman MH, et al. Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Nature Communications. 2015;6(May).
- Smets I, Fiddes B, Garcia-Perez JE, He D, Mallants K, Liao W, et al. Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells. Brain. 2018;141(3):786–96. [PubMed: 29361022]
- Nourbakhsh B, Rutatangwa A, Waltz M, Rensel M, Moodley M, Graves J, et al. Heterogeneity in association of remote herpesvirus infections and pediatric MS. Annals of Clinical and Translational Neurology. 2018 Oct 1;5(10):1222–8. [PubMed: 30349857]
- Chen CY, Pollack S, Hunter DJ, Hirschhorn JN, Kraft P, Price AL. Improved ancestry inference using weights from external reference panels. Bioinformatics. 2013 Jun 1;29(11):1399–406. [PubMed: 23539302]
- Lavery AM, Collins BN, Waldman AT, Hart CN, Bar-Or A, Marrie RA, et al. The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk. Multiple Sclerosis Journal [Internet]. 2019 Apr 1 [cited 2020 Aug 15];25(4):515–22. Available from: https:// pubmed.ncbi.nlm.nih.gov/29393768/ [PubMed: 29393768]
- 19. Vanderweele TJ, Knol MJ. A Tutorial on Interaction. Epidemiol Methods. 2014;3(1):33-72.
- Muller CJ, Maclehose RF. Estimating predicted probabilities from logistic regression: Different methods correspond to different target populations. International Journal of Epidemiology. 2014;43(3):962–70. [PubMed: 24603316]
- 21. Puhan MA, Chandra D, Mosenifar Z, Ries A, Make B, Hansel NN, et al. Ozone, NO2 and PM10 are associated with the occurrence of multiple sclerosis relapses. 2017;37(4):784–90.
- 22. Patsopoulos NA, Barcellos LF, Hintzen RQ, Schaefer C, van Duijn CM, Noble JA, et al. Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects. PLoS Genetics. 2013 Nov 1;9(11).
- Poorolajal J, Bahrami M, Karami M, Hooshmand E. Effect of smoking on multiple sclerosis: A meta-analysis. Journal of Public Health (United Kingdom). 2017 Jun 1;39(2):312–20.
- Barragán-Martínez C, Speck-Hernández CA, Montoya-Ortiz G, Mantilla RD, Anaya JM, Rojas-Villarraga A, et al. Organic Solvents as Risk Factor for Autoimmune Diseases: A Systematic Review and Meta-Analysis. PLoS ONE. 2012 Dec 19;7(12):e51506. [PubMed: 23284705]
- 25. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993;366(6450):76–9. [PubMed: 7694153]
- 26. Kuchroo VK, Prabhu Das M, Brown JA, Ranger AM, Zamvil SS, Sobel RA, et al. B7–1 and B7–2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell. 1995 Mar 10;80(5):707–18. [PubMed: 7534215]
- 27. Niino M, Hirotani M, Miyazaki Y, Sasaki H. Memory and naïve B-cell subsets in patients with multiple sclerosis. Neuroscience Letters. 2009 Oct 16;464(1):74–8. [PubMed: 19666086]

- Fraussen J, Claes N, Van Wijmeersch B, van Horssen J, Stinissen P, Hupperts R, et al. B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responses. Clinical Immunology. 2016 Dec 1;173:124–32. [PubMed: 27717695]
- Filion LG, Matusevicius D, Graziani-Bowering GM, Kumar A, Freedman MS. Monocyte-derived IL12, CD86 (B7–2) and CD40L expression in relapsing and progressive multiple sclerosis. Clinical Immunology. 2003 Feb 1;106(2):127–38. [PubMed: 12672403]
- Zeinstra E, Wilczak N, De Keyser J. Reactive astrocytes in chronic active lesions of multiple sclerosis express co-stimulatory molecules B7–1 and B7–2. Journal of Neuroimmunology. 2003;135(1–2):166–71. [PubMed: 12576238]
- Sawcer S, Hellenthal G, Pirinen M, Spencer CCA, Patsopoulos NA, Moutsianas L, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Vol. 476, Nature. Europe PMC Funders; 2011. p. 214–9.
- 32. Rühl G, Niedl AG, Patronov A, Siewert K, Pinkert S, Kalemanov M, et al. Multiple sclerosis: Molecular mimicry of an antimyelin HLA class I restricted T-cell receptor. Neurology: Neuroimmunology and NeuroInflammation. 2016;3(4).
- Friese MA, Jakobsen KB, Friis L, Etzensperger R, Craner MJ, McMahon RM, et al. Opposing effects of HLA class I molecules in tuning autoreactive CD8 + T cells in multiple sclerosis. Nature Medicine. 2008 Nov;14(11):1227–35.
- Rothman KJ, Greenland S, Walker AM. Concepts of interaction. American Journal of Epidemiology. 1980;112(4):467–70. [PubMed: 7424895]
- 35. Abdul Shakor AS ad, Pahrol MA, Mazeli MI. Effects of Population Weighting on PM10 Concentration Estimation. Journal of Environmental and Public Health. 2020;2020.




Figure 1: High ozone levels, *DRB1* and *CD86* SNP GG genotype are associated with pediatric onset MS risk.

Odds ratio with 95 % confidence interval of developing MS. Adjusted odds ratios are calculated based on separate logistic regression models adjusted for age, sex, genetic ancestry, and mother's education. **: P-value <0.01, ***: P-value <0.001

Table 1.

Characteristics of study participants.

Characteristics	POMS (n=334)	Healthy controls (n=565)	P-value
Age, median years (IQR)	15 (3)	15 (5)	0.09 ^{<i>a</i>}
Female, n (%)	216 (64.6)	336 (59.5)	0.13 ^b
Ratio, F:M	1.8:1	1.46:1	
Self-reported race, n (%)			
White	227 (67.9)	368 (65.2)	h
Non-White	107 (32.0)	196 (34.7)	0.42 ^b
Self-reported ethnicity, n (%)			
Hispanic	97 (30.0)	115 (20.8)	h
Non-Hispanic	226 (69.9)	437 (79.1)	0.002 ^b
Genetic ancestry estimation, mean (SD)			
European ancestry percentage	68.4 (0.3)	67.7 (0.3)	$0.72^{\mathcal{C}}$
East Asian ancestry percentage	3.5 (0.1)	7.5 (0.2)	0.003 ^C
Native American ancestry percentage	10.1 (0.1)	6.6 (0.1)	0.003 ^C
West African ancestry percentage	17.8 (0.2)	18.1 (0.2)	$0.85^{\mathcal{C}}$
Mother's education, n (%)			
Less than high school	17 (6.1)	5 (1.0)	
High school and college	156 (56.3)	240 (48.0)	< 0.001 ^d
University degree	104 (37.5)	255 (51.0)	
County-level ozone, n (%)			
Tertile 1	60 (17.9)	190 (33.6)	
Tertile 2	148 (44.3)	187 (33.0)	< 0.001 ^d
Tertile 3	126 (37.7)	188 (33.2)	

POMS: Pediatric onset multiple sclerosis; IQR: interquartile range.

^aMann Whitney test

^bFisher's exact test

^cUnpaired t test, test

^dChi-squared test

Page 14

Table 2.

Distribution of genetic covariates between POMS and healthy control participants.

Genetic covariates	POMS	Healthy controls
HLA-DRB1*15	n=321	n=556
Presence of one or two alleles, n (%)	127 (39.6)	139 (25.0)
CD86 SNP (rs9282641, G/A)	n=318	n=555
Presence of GG genotype, n (%)	290 (91.1)	465 (83.7)
HLA-A*02	n=285	n=442
Absence of one or two alleles, n (%)	175 (61.4)	248 (56.1)

POMS: Pediatric-Onset Multiple Sclerosis; SNP: Single Nucleotide Polymorphism

Table 3.

Stratified analyses assessing additive interactions between high ozone levels and presence of *HLA-DRB1*15* allele, *CD86* SNP GG genotype, and absence of *HLA-A*02*.

High ozone levels (Tertiles 2 and 3)	Presence of HLA-DRB1*15	Ca/Co	OR (95% CI)	RERI (95% CI)	AP (95% CI)
-	-	44/140	1 (reference)		
-	+	15/48	0.99 (0.50-1.95)		
+	-	150/277	1.68 (1.12–2.53)*		
+	+	112/91	3.89 (2.47–6.12)***	2.21 (0.83– 3.59) ^{**}	0.56 (0.33– 0.79) ***
High ozone levels (Tertiles 2 and 3)	Presence of <i>CD86</i> SNP, GG.				
-	-	4/20	1 (reference)		
-	+	55/168	1.72 (0.56–5.34)		
+	-	24/70	1.79 (0.55–5.81)		
+	+	235/297	4.06 (1.36–12.14)*	1.60 (0.14–3.06)*	0.37 (0.001– 0.75) *
High ozone levels (Tertiles 2 and 3)	Absence of <i>HLA-A*02</i>				
-	-	22/49	1 (reference)		
-	+	32/95	0.67 (0.35–1.30)		
+	_	88/145	1.22 (0.68–2.19)		
+	+	143/153	1.90 (1.08–3.35)*	1.55 (0.78– 2.32) ***	0.52 (0.15– 0.89) ^{**}

Ca/Co: Number of POMS cases and healthy controls; RERI: Relative Excess Risk due to Interaction; AP: Attributable Proportion of disease; CI: Confidence Intervals.

*P-value <0.05

** P-value <0.01

*** P-value <0.001

Logistic regression models were adjusted for age, sex, genetic ancestry, and mother's education.

Table 4.

Models assessing multiplicative interactions for odds of POMS.

	Model 1	Model 2	Model 3	Model 4
	No interaction term	Interaction term, Ozone X <i>DRB1*15</i> +	Interaction term, Ozone X CD86 GG +	Interaction term, Ozone X <i>A</i> *02 –
	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)
High ozone exposure (Tertiles 2&3)	2.22 (1.57–3.13)***	1.68 (1.12–2.53)*	1.79 (0.55–5.81)	1.22 (0.68–2.19)
Secondary risk factors (<i>DRB1*15 +</i> , <i>CD86</i> GG+, <i>A*02 –</i>)	-	0.99 (0.50–1.95)	1.72 (0.56–5.34)	0.67 (0.35–1.30)
High ozone X HLA-DRB1*15 (+)	-	2.32 (1.08–4.99)*	-	-
High ozone X <i>CD86</i> SNP, GG (+)	-	-	1.31 (0.38–4.48)	-
High ozone X HLA-A*02 (-)	-	-	-	2.29 (1.08–4.84)*
Pseudo R ²	0.044	0.063	0.054	0.043
Log likelihood	-546.74	-535.13	-540.25	-464.95

*. P-value <0.05

**: P-value <0.01

***: P-value <0.001

The logistic regression models were adjusted for age, sex, genetic ancestry, and mother's education.